Dr. Roger Rich represents companies in areas of patent law related to biotechnology and pharmaceuticals. He advises clients in the strategic development, management, and prosecution of patent portfolios involving technologies such as small molecule pharmaceuticals, genetic analyses, biologics, nutraceuticals, and transgenic animals, among others. Representative clients have included AbbVie, Acadia Pharmaceuticals, Amgen, AstraZeneca, Becton Dickinson, and Genentech, as well as other start-up companies, established companies, academic institutions, and investment firms.
In addition to patent procurement and portfolio management, Roger advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition.
- March 27, 2019
Intellectual Property and Plants
- Santa Clara University (J.D. 2002; Sr. Technical Editor, Santa Clara Law Review); Stanford University (Postdoctoral Fellow, 1996-1999); University of California, Irvine (Ph.D. in Biological Sciences 1996); San Jose State University (B.S. in Chemistry [Biochemistry] 1989, with honors in Chemistry)
- California and registered to practice before the United States Patent and Trademark Office